| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Fazirsiran | TAK-999; ADS-001; ARO-AAT | Phase 3 Clinical | Arrowhead Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd | alpha 1-Antitrypsin Deficiency; Hepatic Insufficiency | Details |
| YOLT-202 | YOLT-202 | Phase 3 Clinical | Shanghai Yaotang Biotechnology Co Ltd | alpha 1-Antitrypsin Deficiency; Genetic Diseases, Inborn | Details |
| Efdoralprin alfa | INBRX-101; AT-292; rhAAT-Fc; AAT-IgG-Fc; AAT-Fc; SAR447537; SAR-447537 | Phase 2 Clinical | Arecor Ltd, Inhibrx | alpha 1-Antitrypsin Deficiency; Emphysema | Details |
| TSRA-196 | TSRA-196 | Phase 2 Clinical | Tessera Therapeutics Inc | alpha 1-Antitrypsin Deficiency | Details |
| VX-864 | VX-864 | Phase 2 Clinical | Vertex Pharmaceuticals Incorporated | alpha 1-Antitrypsin Deficiency | Details |
| KRRO-110 | KRRO-110 | Phase 2 Clinical | Korro Bio Inc | alpha 1-Antitrypsin Deficiency | Details |
| WVE-006 | WVE-006; GSK-5462688 | Phase 2 Clinical | Wave Life Sciences Ltd | alpha 1-Antitrypsin Deficiency | Details |
| BEAM-302 | α1-AD; α-1-AD; BEAM-302 | Phase 2 Clinical | Beam Therapeutics Inc | alpha 1-Antitrypsin Deficiency | Details |
| adeno-associated virus gene therapy (University of Massachusetts/University of Florida/NHLBI) | Phase 1 Clinical | University of Massachusetts | alpha 1-Antitrypsin Deficiency | Details | |
| KB-408 | KB-408 | Phase 1 Clinical | Krystal Biotech Inc | alpha 1-Antitrypsin Deficiency | Details |
| VX-668 | VX-668; VX668 | Phase 1 Clinical | Vertex Pharmaceuticals Incorporated | alpha 1-Antitrypsin Deficiency | Details |
| VX-634 | VX-634 | Phase 1 Clinical | Vertex Pharmaceuticals Incorporated | alpha 1-Antitrypsin Deficiency | Details |
| BMN-349 | BMN-349 | Phase 1 Clinical | Biomarin Pharmaceutical Inc | alpha 1-Antitrypsin Deficiency | Details |
| Alpha-1 antitrypsin (Kalytera Therapeutics) | Clinical | Clalit Health Services | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Alpha1-proteinase inhibitor (Human, Grifols) | TAL-6004 | Approved | Bayer AG, Grifols Sa | Prolastin, Prolastin-c | United States | alpha 1-Antitrypsin Deficiency | null | 1987-12-02 | alpha 1-Antitrypsin Deficiency; Coronavirus Disease 2019 (COVID-19); Cystic Fibrosis; Pancreatitis, Chronic; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema | Details |
| Alfalastin (LFB SA) | Approved | Lfb Biotechnologies Sas | Alfalastin | France | alpha 1-Antitrypsin Deficiency | Lfb Biotechnologies Sas | 2005-08-01 | alpha 1-Antitrypsin Deficiency | Details |